Bryan Johnson Visceral Fat: Methods and UK Evidence

Bryan Johnson's visceral fat reduction efforts have drawn widespread attention as part of his Blueprint longevity project. Visceral fat, the metabolically active fat stored around the internal organs, is linked to insulin resistance, cardiovascular disease and type 2 diabetes, making it a clinically meaningful target. Johnson uses intensive tracking methods, a structured plant-based diet and daily exercise to minimise his visceral fat levels. This article examines his approach, what UK clinical evidence says about reducing visceral fat, and what practical steps are supported by NHS and NICE guidance.

Who is Bryan Johnson and why is he focused on visceral fat?

Bryan Johnson is a technology entrepreneur whose Blueprint longevity project targets visceral fat reduction, based on research linking it to insulin resistance, cardiovascular disease and accelerated biological ageing, though his methods go beyond standard clinical recommendations.

Bryan Johnson is an American technology entrepreneur who sold his company Braintree to PayPal in 2013 and subsequently dedicated a significant portion of his resources to a personal longevity project he calls Blueprint, with visceral fat reduction as one of its central targets. Johnson has spoken publicly about his belief that excess visceral fat accelerates biological ageing and drives systemic inflammation, though these are his personal views and hypotheses rather than established clinical conclusions. His project involves a team of physicians, scientists and data analysts who monitor dozens of biomarkers on a regular basis.

Johnson's focus on visceral fat is grounded in the growing body of research linking this specific fat depot to insulin resistance, type 2 diabetes, cardiovascular disease and all-cause mortality, associations that are recognised in UK clinical guidance including NICE recommendations on obesity and cardiovascular risk assessment. Unlike subcutaneous fat, which sits beneath the skin, visceral fat surrounds the internal organs and is metabolically active in ways that can disrupt hormonal and inflammatory signalling.

Johnson has described his personal aim as reducing central adiposity to the lower end of healthy ranges, though it is important to note that UK clinical guidance frames visceral fat management in terms of reducing risk rather than achieving any specific absolute minimum. His methods attract both scientific interest and scepticism, and many of the interventions he uses go well beyond standard clinical recommendations.

It is worth noting that Johnson's approach is self-funded, highly individualised and not a clinical protocol endorsed by any UK regulatory or health body. The educational value of his public documentation lies in raising awareness of visceral fat as a health marker, even if his specific regimen is not generalisable to the wider population.

What is visceral fat and why does it matter for your health?

Visceral fat surrounds internal organs and releases inflammatory cytokines and fatty acids into the portal circulation, raising the risk of type 2 diabetes, cardiovascular disease, dyslipidaemia and MASLD.

Visceral fat is the metabolically active adipose tissue stored within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it is associated with a substantially higher cardiometabolic risk than subcutaneous fat stored beneath the skin. Unlike subcutaneous fat, visceral fat releases fatty acids, inflammatory cytokines and hormones directly into the portal circulation, which supplies the liver.^[1] This proximity to the liver means that excess visceral fat is closely linked to metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), insulin resistance and dyslipidaemia.

NICE guidance on obesity and cardiovascular risk recognises waist circumference as a clinically useful proxy for central adiposity, which correlates with visceral fat accumulation. For people of White European origin, a waist circumference above 94 cm in men and 80 cm in women is considered to indicate increased risk, with thresholds of 102 cm and 88 cm respectively indicating high risk.^[2][3] For people of South Asian, Chinese and Japanese origin, lower thresholds apply: increased risk is indicated at waist circumferences above 80 cm in women and above 90 cm in men, reflecting differing patterns of fat distribution at equivalent body mass index values.^[2][4] These thresholds are set out in NHS and NICE guidance on cardiovascular risk assessment.

Visceral fat is not static. Evidence from clinical studies suggests it responds to dietary change, physical activity, sleep quality and stress management, though the degree to which it responds differently from subcutaneous fat varies between individuals and study populations. This responsiveness makes it a meaningful target for lifestyle intervention. Elevated visceral fat is associated with:

• Increased risk of type 2 diabetes

• Higher cardiovascular disease risk

• Raised blood pressure and triglycerides

• Low HDL cholesterol

• Systemic low-grade inflammation

For patients and clinicians, visceral fat is best understood not as a cosmetic concern but as a modifiable risk factor with direct implications for long-term health outcomes.

How does Bryan Johnson measure and track his visceral fat levels?

Johnson uses DEXA scanning and MRI to quantify visceral fat; for most UK individuals, waist circumference, waist-to-height ratio and blood biomarkers are the practical, evidence-aligned alternatives recommended by NICE.

Bryan Johnson primarily uses dual-energy X-ray absorptiometry (DEXA) scanning to quantify his visceral fat, alongside magnetic resonance imaging (MRI) for more detailed organ-level assessment, and he publishes his results publicly as part of the Blueprint project's transparency ethos. DEXA scanning provides a whole-body composition analysis that distinguishes between lean mass, subcutaneous fat and visceral fat area, and it is considered one of the more accessible and reproducible methods for tracking visceral fat over time in a clinical or research setting. DEXA does involve a small dose of ionising radiation; while this is low, repeated scanning should be considered in proportion to clinical need rather than undertaken routinely without indication.

In the UK, DEXA body composition scanning is available privately and, in some circumstances, through NHS services for specific clinical indications such as assessment of bone density. It is not routinely offered as a general health screening tool on the NHS. MRI-based visceral fat quantification, which Johnson also uses, is more precise but considerably more expensive and less widely available outside research environments.

For most people in the UK, practical proxies for visceral fat include waist circumference measurement, waist-to-hip ratio and waist-to-height ratio. These are inexpensive, reproducible and recommended by NICE and NHS guidance as part of cardiovascular risk assessment. A waist-to-height ratio below 0.5 is broadly associated with lower cardiometabolic risk in adults, a threshold referenced in NICE guidance. Blood biomarkers such as fasting glucose, HbA1c, triglycerides, HDL cholesterol and liver enzymes (particularly ALT) can also provide indirect evidence of visceral adiposity and its metabolic consequences.

Johnson's approach to tracking is unusually intensive and resource-heavy. For most individuals, a combination of waist circumference measurement and periodic blood tests reviewed by a GP or practice nurse represents a proportionate and evidence-aligned monitoring strategy, with imaging reserved for cases where clinical assessment indicates a need.

Which diet and lifestyle changes does he use to reduce visceral fat?

Johnson follows a whole-food plant-based diet with time-restricted eating, daily aerobic and resistance exercise, strict sleep hygiene and no alcohol, all of which align broadly with NHS and NICE recommendations for reducing central adiposity.

Bryan Johnson follows a structured, predominantly whole-food plant-based diet with a strict caloric target, consistent meal timing and the elimination of ultra-processed foods, alcohol and added sugars, all of which are strategies that align broadly with evidence-based approaches to reducing visceral fat. His dietary pattern emphasises vegetables, legumes, nuts, seeds and olive oil, with a strong focus on fibre intake and minimising glycaemic load. He eats his last meal early in the evening, a practice consistent with time-restricted eating. Some research suggests time-restricted eating may support metabolic health, though the evidence base is still developing and NICE does not currently make a specific recommendation for this approach; it should be considered alongside, rather than instead of, established dietary guidance.

In terms of physical activity, Johnson incorporates daily structured exercise combining cardiovascular training and resistance work. Systematic reviews and randomised controlled trials have found that resistance exercise can reduce visceral fat, including in some studies where overall body weight change was modest, likely through improvements in insulin sensitivity and skeletal muscle glucose uptake.^[10] The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days per week.^[6][7]

His sleep protocol is highly regimented, targeting consistent sleep and wake times, minimal light exposure in the evening and a cool sleeping environment. Research has associated sleep deprivation and circadian disruption with increased visceral fat accumulation, elevated cortisol and impaired glucose regulation, though the direction of causality in some studies is not fully established.

Johnson also reports using stress-reduction practices and avoids alcohol entirely. Chronic psychological stress is associated with raised cortisol, which has been linked to visceral fat deposition in observational and experimental studies.^[8] Alcohol consumption is associated with hepatic fat accumulation and is a recognised contributor to MASLD.^[9]

While Johnson's regimen is far more prescriptive than most people would find practical, the core components, namely a diet rich in fibre and low in ultra-processed foods, regular physical activity, adequate sleep and alcohol reduction, are consistent with NHS and NICE recommendations for reducing central adiposity and improving cardiometabolic health.

What does UK clinical evidence say about reducing visceral fat?

NICE recommends multicomponent lifestyle intervention as first-line treatment for visceral fat reduction, with pharmacological options such as semaglutide or tirzepatide considered where lifestyle change alone is insufficient and clinical criteria are met.

UK clinical guidance supports a combination of dietary modification, increased physical activity and behavioural change as the primary evidence-based approach to reducing visceral fat and the cardiometabolic risks associated with it. NICE guidance on obesity recommends a multicomponent lifestyle intervention as the first-line approach, with pharmacological treatment considered for people who have not achieved sufficient benefit from lifestyle change alone and who meet specific clinical criteria. Readers should note that NICE guidance on obesity is periodically updated; the current applicable guideline should be confirmed via the NICE website.

For dietary change, evidence consistently supports reducing total energy intake, limiting ultra-processed foods, added sugars and saturated fats, and increasing dietary fibre. The Mediterranean dietary pattern, which shares many features with Johnson's approach, has a meaningful evidence base for reducing visceral fat and improving insulin sensitivity. A systematic review and meta-analysis published in the British Journal of Nutrition found that Mediterranean-style diets were associated with significant reductions in waist circumference compared with control diets, though readers seeking the specific citation should consult the journal directly as the reference was not included in the original source material for this article.^[17]

For physical activity, both aerobic exercise and resistance training reduce visceral fat, with combined programmes showing the greatest effect in clinical studies. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days per week.^[6][7]

Where lifestyle change is insufficient, NICE-recommended pharmacological options for weight management in the UK include orlistat and GLP-1 receptor agonists such as semaglutide (Wegovy, available in doses up to 2.4 mg weekly by injection, with a higher-dose 7.2 mg weekly formulation also MHRA-authorised). Tirzepatide (Mounjaro) is also MHRA-authorised for both type 2 diabetes and chronic weight management; it is a dual GIP and GLP-1 receptor agonist, not a GLP-1 receptor agonist alone.^[14][15] This list is not exhaustive: orforglipron (Foundayo) has also received MHRA authorisation for weight management, and further options may be available.^[16] Prescribers will consider individual clinical circumstances, NICE eligibility criteria and local integrated care board (ICB) commissioning pathways when recommending any pharmacological treatment.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support. Medicines such as those named above are only prescribed where a clinician considers them appropriate following individual assessment; they are not available without a valid prescription.

Anyone concerned about their visceral fat levels or cardiometabolic risk should speak to their GP in the first instance, who can arrange relevant investigations and discuss appropriate management options.

Scientific References

1. Visceral fat and metabolic inflammation: the portal theory revisited.
2. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
3. NG246 Full guideline, section 2 – Identification and classification: evidence statements and reviews.
4. NG246 Appendix A1: Summary of evidence from surveillance (PH46).
5. Calculate your waist to height ratio.
6. Physical activity guidelines for adults aged 19 to 64.
7. UK Chief Medical Officers' physical activity guidelines.
8. Stress-induced cortisol response and fat distribution in women.
9. Non-alcoholic fatty liver disease (NAFLD).
10. Exercise for type 2 diabetes mellitus.
11. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity.
12. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
13. Semaglutide – BNF.
14. Tirzepatide – BNF.
15. GLP-1 medicines for weight loss and diabetes: what you need to know.
16. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes.
17. The effects of Mediterranean diet with and without exercise on body composition in adults with chronic disease: a systematic review and meta-analysis of clinical trials.

Frequently Asked Questions